KTRAKintara TherapeuticsKTRA info
$4.48info0.00%24h
Global rank29456
Market cap$7.26M
Change 7d-10.04%
YTD Performance2648.47%
SP500 benchmarkOutperform
P/E-0.48
P/S0
Revenue$0
Earnings-$14.65M
Dividend yield-
Main Sector
Healthcare
Category

Kintara Therapeutics (KTRA) Stock Overview

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

KTRA Stock Information

Symbol
KTRA
Address
9920 Pacific Heights BlvdSan Diego, CA 92121United States
Founded
-
Trading hours
-
Website
https://www.kintara.com
Country
πŸ‡ΊπŸ‡Έ United States
Phone Number
858 350 4364

Kintara Therapeutics (KTRA) Price Chart

-
Value:-

Kintara Therapeutics Overview: Key Details and Summary

Stock data
2023
Change
Price
$4.48
N/A
Market Cap
$7.26M
N/A
Shares Outstanding
1.62M
66.32%
Employees
2.00
N/A
Shareholder Equity
731.00K
-93.80%
Valuation
2023
Change
P/E Ratio
-0.48
N/A
P/B Ratio
9.93
N/A
Growth
2023
Change
Return on Equity
-20.0397
N/A
Earnings
2023
Change
Revenue
$0
N/A
Earnings
-$14.65M
N/A
EPS
-9.27
N/A
Earnings Yield
-2.07
N/A
Financial Strength
2023
Change
Total Assets
$3.98M
N/A
Cash on Hand
$1.53M
N/A
Debt to Equity
$4.44
1161.93%
Current Ratio
$1.06
-68.07%
logo
Facebook Icon
Twitter Icon
Linkedin Icon
Β© 2024 Topstocks.org